Ventana Biotech, Inc. (VNTA)

0.0023 +0.0002 (+9.52%) 收市：09:30AM EDT

Ventana Biotech, Inc.

1 Bachstrasse
Butschwil 9606
Switzerland
41 44 732 60 59

版塊: Financial Services
行業: Shell Companies
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Janne Christensen	Chief Exec. Officer, Pres, Chief Financial Officer, Treasurer and Director	無	無	無
Mr. David Holsworth	Chief Operating Officer, VP and Exec. Director	無	無	無
Ms. Marilyn Thom	VP of Admin. & HR	無	無	無
Mr. Elliott Martin	VP of Sales and Marketing	無	無	無
Mr. Trevor Conn	Exec. Director	無	無	無
Mr. Yoon Youngkeun	Sec. and Director	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders. The company develops appetite suppressant chewing gums, including the low dosage product for the over-the-counter market and the high dosage product for distribution by pharmacists. It intends to market low dosage product though drug and health food stores. The company was formerly known as Personalica, Inc. and changed its name to Ventana Biotech, Inc. in October 2008. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland.

公司管治

截至 無 止，Ventana Biotech, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。